Cutting-edge cancer treatments: expense & expectation? CRUK, 23 February, 2012

Aim of the workshop – For delegates to understand the cost/benefits of new (and existing) technologies and treatments for cancer patients the public expectations of the NHS in providing cancer treatments and the importance of PPI in cancer research and services.


Impact of the workshop –For delegates to apply in their PPI work,an informed patient perspective on the costs/benefits of new (and existing) technologies and treatments for cancer patients in the current economic climate.



Introduction and clarification of aims of the workshop

Richard Stephens, Incoming  Chair of CLG & ICPV Member


What do cancer patients want from the  NHS? - Laura Thomas, Ipsos MORI


Stratified medicine –  What is it and could it reduce costs in long term?

Dr Emily Shaw, Clinical Lead, Stratified Medicine Unit, Cancer Research UK


What is the role of chemoprevention &  do we need to licence drugs for this use? What is the future for use of orphan  drugs?

Professor Jack Cuzick, Wolfson Institute


Imaging in research and early drug  development – role of ECMC What happened to the “Star Wand?”

Prof Kerry Chester UCL , Professor of Molecular Medicine, University College London


Supporting research, protecting patients: Cancer Research UK's recommendations to reform the Clinical Trials Directive (for report on the reform go to our resources page

Emma Greenwood, Policy Manager, CRUK


Delivering World  Class Radiotherapy

Tim Cooper, Associate Director-Radiotherapy, National Cancer Action Team


New models of radiotherapy

Dr Jayant Vaidya,  Breast Cancer Specialist, University College London


How do we achieve cost effective cancer treatments in the UK?

Prof Peter Littlejohns Kings College London & previously at NICE


Drug pricing issues - Rob Day, Head of Oncololgy, Pfizer


Relationships between the pharma industry and patients - Stuart Pritchard, GSK


Click here for speakers presentations, review of the day and images



AllTrials logo


VOICE 2022

We are pleased to announce that the VOICE course will be residential and held at Barts Cancer Centre from 4-8 Sept. Click here for further details.


OPTIMA is a patient driven clinical study for people with hormone sensitive early breast cancer. 

OPTIMA aims to improve the way we make decisions about whom we offer chemotherapy to following surgery.
Check the website link for more information or listen to the short video to explain the trial.


Immunology Talk

On the 25th March we held an interactive talk and discussion on immunology.

The talk was given by Dr Edd James, Cancer Immunologist from the university of Southampton. The tallk is now available on YouTube - click here to listen. 


Long Term Survivor Study 

Continuum Life Sciences are looking for volunteers who have survived aggressive, difficult to treat cancer against all odds to take part in their Long-Term Survivor of Cancer Study. For more information and how you can join go to their website.


Save the planet and donate to ICPV - send ecards go tour Fundraising page for mor information.

FAST-Forward Trial Results

A one-week course of radiotherapy in fewer but larger daily doses was found to be as safe and effective as standard three-week therapy for women following surgery for early stage breast cancer. Trial results now published. Two ICPV members provided the PPI for this key trial. Full details can be found on the ICR Website.

ICPV Brighton Summer School Aug 2019

ICPV was once again hosted by SHORE-C at the University of Sussex. Click here for more info.

San Antonio Breast Cancer Symposium, 2018

ICPV member Pat Fairbrother attended this event on an Alamo Foundation Scholarship. Click here to read her review.

Gap Analysis in Breast Surgery Published

The 2013 Breast Cancer Campaign gap analysis established breast cancer research priorities without a specific focus on surgical research or the role of surgeons on breast cancer research. This Review aims to identify opportunities and priorities for research in breast surgery to complement the 2013 gap analysis. Click here for more information

ICPV Review 2018
We have at last published a new edition of our review. This was achieved by a grant from Novartis. Click here for more information. 

Award for ICPV Member

Many congratulations to ICPV member Margaret Grayson. On 21 April 2018 she received the Iris Colvin Lifetime Achievement Award for Health, presented by the Women’s Forum of Northern Ireland. This is very well deserved for her tireless work in furthering cancer research especially in Northern Ireland.

Contact us by email



Or use our online contact form